Universal Omics

At Universal Omics, we take pride in being a key player in the field of biotechnology, specializing in the in silico design of drugs and the analysis of bioactives, existing drugs and nutraceuticals for cardiac disease and other metabolic impairments. Our distinctive focus on repairing and regulating the cell membrane positions us uniquely to tackle global health challenges and enhance people's quality of life. Our vision stemmed from a multidisciplinary team of experts in biotechnology and artificial intelligence aiming to address the growing unmet needs in the treatment of non-communicable diseases, such as cardiac disease, particularly arrhythmia. With approximately 18 million people dying each year from cardiovascular diseases, where 15-20% of deaths are attributed to arrhythmias, we are uniquely positioned in the market to address these critical needs. We have developed a deep learning tool called DRUP-Drug Predictor, which gives us a significant competitive advantage by enabling precise prediction of the efficacy of any molecule of any size or shape under different conditions and doses. This not only streamlines the drug development process but also ensures the safety and efficacy of the end products. Additionally, we offer specialized services through the DRUP-Drug Predictor software, including: -High throughput screening of biomolecules (bioactives) with anti-arrhythmic activity. -Analysis of the effectiveness of existing drugs and nutraceuticals. -Design of new or redesign of existing drugs and nutraceuticals. Our mission is to provide innovative and personalized solutions that drive significant advancements in the treatment of non-communicable diseases with a focus on the absence of adverse effects in the medium and long term. If you are seeking strategic partners in your quest for more effective and safer treatments, contact us today! Together, we can transform the landscape of healthcare If info@universal-omic